## Asymmetric Hydrogenation of 2-Arylated Cycloalkanones through Dynamic Kinetic Resolution

Takeshi Ohkuma, Jing Li, Ryoji Noyori\*

Department of Chemistry and Research Center for Materials Science, Nagoya University, Chikusa, Nagoya 464-8602, Japan Fax +81(52)7834177; E-mail: noyori@chem3.chem.nagoya-u.ac.jp

Received 1 March 2004

Dedicated to Professor Clayton H. Heathcock in recognition of his significant contribution to organic synthesis and basic science.

**Abstract:** Asymmetric hydrogenation of 2-arylcycloalkanones with *trans*-RuCl<sub>2</sub>(binap)(1,2-diamine) and t-C<sub>4</sub>H<sub>9</sub>OK in 2-propanol selectively gives the corresponding *cis*-2-arylcycloalkanols in excellent enantiomeric purity and high yield. Two synthetic intermediates of biologically active compounds have been prepared by this method.

**Key words:** 2-arylcycloalkanones, asymmetric hydrogenation, BINAP, dynamic kinetic resolution, ruthenium complexes

Under suitable conditions, asymmetric hydrogenation of certain configurationally labile chiral ketones can lead to single isomeric alcohols out of four possible stereoisomers.<sup>1,2</sup> Thus hydrogenation of a racemic  $\alpha$ -substituted ketone with RuCl<sub>2</sub>(binap)(1,2-diamine)<sup>3,4</sup> and an alkaline base in 2-propanol gives a single chiral alcohol selectively and in high yield.<sup>5–7</sup> In this reaction, a chiral Ru hydride species generated from the RuCl<sub>2</sub> precatalyst reduces a ketone enantiomer (kinetic resolution) selectively with a high *cis:trans* diastereoselectivity. The slow-reacting ketone enantiomer is facilely racemized due to the protic basic conditions and both enantiomers consequently serve as hydrogenation substrates. We describe here the enantioand diastereoselective hydrogenation of 2-arylcycloalkanones (1-3) to cis-2-arylcyclohexanols (4-6) of high enantiomeric purity under dynamic kinetic resolution (Scheme 1).<sup>1,8</sup> In addition, this method has been applied to the synthesis of certain important chiral building blocks.

First, we selected 2-phenylcyclohexanone (**2a**) as a standard substrate. When racemic **2a** was hydrogenated in 2propanol containing *trans*-RuCl<sub>2</sub>[(*R*)-tolbinap][(*R*,*R*)dpen] [(*R*,*RR*)-**7a**]<sup>4d</sup> and *t*-C<sub>4</sub>H<sub>9</sub>OK {[**2a**] = 0.5 M, [*t*-C<sub>4</sub>H<sub>9</sub>OK] = 15 mM, ketone:Ru = 10,000:1} at 8 atm of H<sub>2</sub> and 25 °C for 24 hours, (1*S*,2*S*)-2-phenylcyclohexanol [(1*S*,2*S*)-**5a**] was obtained in 99.7% ee and 100% yield. The *cis* diastereoselectivity was perfect. The bulky RuH(diamine) intermediate delivers a hydride on Ru and a proton on nitrogen to the carbonyl function via a sixmembered pericyclic transition state.<sup>9</sup> As illustrated in Scheme 2, the (*R*)-BINAP–(*R*,*R*)-DPEN-combined complex kinetically selects (*S*)-**2a** with its stable chair conformer possessing an equatorial phenyl substituent, and

SYNLETT 2004, No. 8, pp 1383–1386 Advanced online publication: 22.06.2004 DOI: 10.1055/s-2004-829093; Art ID: Y01304ST © Georg Thieme Verlag Stuttgart · New York



## Scheme 1

approaches the C=O function from the equatorial direction,<sup>10</sup> resulting in the 1*S*,2*S*-product. This reaction is highly productive. Thus, the reaction of 9.12 g of **2a** using 0.5 mg of (*R*,*RR*)-**7a**, viz., substrate:catalyst = 100,000:1, at 8 atm of H<sub>2</sub> and 25 °C was completed in 48 hours to quantitatively afford (1*S*,2*S*)-**5a** in 99.6% ee.<sup>11</sup> The diastereomeric (*R*)-TolBINAP–(*S*,*S*)-DPEN-based Ru complex, (*R*,*SS*)-**7b**, is even more active than (*R*,*RR*)-**7a** but slightly less stereoselective, giving (1*S*,2*S*)-**5a** in 97% ee.

Various 2-arylated cyclohexanones can be used consistently, although the extent of enantio- and/or diastereoselectivity is influenced by the substituents, as exemplified in Table 1. Hydrogenation of the *p*-methoxyphenyl derivative **2b** in the presence of (*R*,*RR*)-**7a** resulted (1*S*,2*S*)-**5b** in 99.5% ee and 100% *cis* selectivity, while the *p*-trifluoromethylphenyl analogue **2c** gave (1*S*,2*S*)-**5c** with a lower stereoselectivity (98% ee, 99.9% *cis*) under similar reaction conditions.<sup>12</sup> Hydrogenation of 2-(2'-naphthyl)cyclohexanone (**2e**) with (*R*,*RR*)-**7a** afforded (1*S*,2*S*)-**5e** in



Scheme 2

>99% ee and a *cis:trans* selectivity of >99:1,<sup>12</sup> but the reaction of the 1'-naphthyl derivative **2d** proceeded less stereoselectively to give (1*S*,2*S*)-**5d** in 93% ee and with a *cis:trans* selectivity of 98:2, due to changes in the steric parameters.

The skeletal change in ketonic substrates requires the modification of the catalyst structures (Table 1). Hydrogenation of 2-phenylcycloheptanone (**3a**) under the standard conditions using (R,RR)-**7a** (ketone:Ru = 2000:1, 8 atm, 25 °C, 27 h) gave (1S,2S)-2-phenylcycloheptanol [(1S,2S)-**6a**] in only 84% ee and 90% yield, albeit with

perfect *cis* selectivity.<sup>12</sup> However, the enantioselectivity and rate were significantly enhanced by the use of diastereomeric (*R*,*SS*)-**7b** as a precatalyst, resulting in (*S*,*S*)-**6a** (100% *cis*) with 95% ee and 100% yield after 24 hour reaction. Hydrogenation of the lower homologue, 2-phenylcyclopentanone (**1a**), with (*R*,*RR*)-**7a** or (*R*,*SS*)-**7b** (ketone:Ru = 2000:1, 8 atm, 25 °C, 36–48 h) gave (1*S*,*2S*)-2-phenylcyclopentanol [(1*S*,*2S*)-**4a**] in 80% ee (*cis:trans* = 94.5:5.5) and 76% ee (*cis:trans* = 100:0), respectively. Fortunately, however, when an (*R*)-XylBI-NAP–(*R*)-DAIPEN-based Ru complex [(*R*,*R*)-**8**]<sup>3,4e</sup> was used, the 1*S*,2*S*-alcohol was obtained in 98% ee and 100% *cis* selectivity.

Notably, this asymmetric hydrogenation under dynamic kinetic resolution is applicable to ketonic substrates possessing an azacyclohexanone skeleton (Figure 1). Thus, the hydrogenation of  $9^{13}$  with (*R*,*RR*)-7a and *t*-C<sub>4</sub>H<sub>9</sub>OK in 2-propanol {[**9**] = 0.125 M, [t-C<sub>4</sub>H<sub>9</sub>OK] = 19 mM, ketone: Ru = 500:1, 8 atm, 20 h produced (2S,3S)-10 in 96% ee and quantitative yield with a 96:4 cis:trans selectivity  $\{ [\alpha]_D^{25} + 29.9 \ (c \ 0.39, CH_3OH) \}$ .<sup>14</sup> This chiral alcohol is convertible to the hNK1 antagonists L-733,06015 and L-741,671.<sup>16</sup> Furthermore, the *m*-methoxyphenyl ketone  $11^{17}$  was hydrogenated with (*S*,*SS*)-7a {[11] = 0.125 M,  $[t-C_4H_9OK] = 25 \text{ mM}$ , ketone:Ru = 500:1, 8 atm, 25 °C, 24 h} quantitatively and stereoselectively to (3S,4R)-12 in 97% ee with a *cis:trans* selectivity of >99:1 { $[\alpha]_D^{25}$  -55.9  $(c 0.40, CH_3OH)$ .<sup>12</sup> This product serves as a synthetic intermediate of (–)-precramol, which is known as a  $D_2/D_3$ auto and sigma receptor agonist.<sup>18</sup>

 Table 1
 Asymmetric Hydrogenation of Racemic 2-Arylated Cycloalkanones 1–3<sup>a</sup>

	Conditions					Alcohol			
								ner	
Ketone	Complex	Ketone:Ru	$[t-C_4H_9OK]$ (mM)	Time (h)	Yield <sup>b</sup> (%)	cis:trans <sup>b</sup>	ee (%) <sup>c</sup>	Config. <sup>d</sup>	$\left[ \alpha \right]_{\mathrm{D}} (^{\circ})^{\mathrm{e}}$
1a	( <i>R</i> , <i>R</i> )- <b>8</b>	2,000:1	50	96	100	100:0	98	1 <i>S</i> ,2 <i>S</i>	+79.8 (c 1.01)
2a	( <i>R</i> , <i>RR</i> )- <b>7a</b>	10,000:1	15	24	100	100:0	99.7	1 <i>S</i> ,2 <i>S</i>	-
2a <sup>g</sup>	( <i>R</i> , <i>RR</i> )- <b>7</b> a	100,000:1	18	48	100	100:0	99.6	1 <i>S</i> ,2 <i>S</i>	+103.6 ( <i>c</i> 2.02) <sup>f</sup>
2a	( <i>R</i> , <i>SS</i> )-7b	2,000:1	25	4	99.6	100:0	97	1 <i>S</i> ,2 <i>S</i>	-
2b	( <i>R</i> , <i>RR</i> )- <b>7</b> a	2,000:1	5	4	100	100:0	99.5	1 <i>S</i> ,2 <i>S</i> <sup>h</sup>	+85.0 (c 1.60)
2c	( <i>R</i> , <i>RR</i> )- <b>7</b> a	2,000:1	6	4	99.9	99.9:0.1	98	1 <i>S</i> ,2 <i>S</i> <sup>h</sup>	+59.6 (c 0.30)
2d	( <i>R</i> , <i>RR</i> )- <b>7a</b>	2,000:1	9	16	>99	98:2	93	1 <i>S</i> ,2 <i>S</i>	+145.0 (c 0.90)
2e	( <i>R</i> , <i>RR</i> )- <b>7</b> a	2,000:1	10	4	>99	>99:1	>99	1 <i>S</i> ,2 <i>S</i> <sup>h</sup>	+47.4 (c 0.20)
3a	( <i>R</i> , <i>SS</i> )- <b>7b</b>	2,000:1	25	24	100	100:0	95	1 <i>S</i> ,2 <i>S</i> <sup>h</sup>	+93.3 (c 0.21)

<sup>a</sup> Reactions were conducted at 25 °C under 8 atm of H<sub>2</sub> using a 0.5 M solution of the ketone in 2-propanol.

<sup>b</sup> Determined by GC, HPLC, and <sup>1</sup>H NMR analysis.

<sup>c</sup> Determined by chiral GC or HPLC analysis.

<sup>d</sup> Determined by the sign of rotation.

<sup>e</sup> A cis-alcohol purified using a silica-gel column. Measured in CHCl<sub>3</sub> at 22–24 °C.

<sup>f</sup> Measured in CH<sub>3</sub>OH.

<sup>g</sup> Reaction using 9.12 g of **2a** in 100 mL of 2-propanol.

<sup>h</sup> Estimated by <sup>1</sup>H NMR measurement after conversion to diastereomeric compounds according to ref.<sup>12</sup>

Synlett 2004, No. 8, 1383-1386 © Thieme Stuttgart · New York



Thus, the asymmetric hydrogenation of racemic 2-arylcycloalkanones through dynamic kinetic resolution, when coupled with previous methods, provides a practical tool for the synthesis of *cis*-2-substituted cycloalkanols and aza-analogues of high enantiomeric purity, which are otherwise difficult to prepare. The optimum conditions are obtained by the careful selection of structural parameters in the BINAP–diamine Ru catalysts. The reaction is achievable with low catalyst loading (ketone:Ru ratio of up to 100,000:1) and under relatively low hydrogen pressure (8 atm) at room temperature.

## Acknowledgment

This work was financially supported by grants-in-aid from the Japan Society for the Promotion of Science (JSPS) (Nos. 14GS0214 and 15350079).

## References

- (1) Noyori, R.; Tokunaga, M.; Kitamura, M. Bull. Chem. Soc. Jpn. **1995**, 68, 36.
- (2) For the first example, see: Noyori, R.; Ikeda, T.; Ohkuma, T.; Widhalm, M.; Kitamura, M.; Takaya, H.; Akutagawa, S.; Sayo, N.; Saito, T.; Taketomi, T.; Kumobayashi, H. J. Am. Chem. Soc. **1989**, 111, 9134.
- (3) (a) Noyori, R.; Ohkuma, T. *Angew. Chem. Int. Ed.* 2001, 40, 40. (b) BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl. TolBINAP = 2,2'-bis(di-4-tolylphosphino)-1,1'-binaphthyl. XylBINAP = 2,2'-bis(di-3,5-xylylphosphino)-1,1'-binaphthyl. DAIPEN = 1,1-di(4-anisyl)-2-isopropyl-1,2-ethylenediamine. DPEN = 1,2-diphenylethylene diamine.
- (4) (a) Ohkuma, T.; Ooka, H.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1995, 117, 2675.
  (b) Ohkuma, T.; Ooka, H.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1995, 117, 10417. (c) Ohkuma, T.; Ikehira, H.; Ikariya, T.; Noyori, R. Synlett 1997, 467. (d) Doucet, H.; Ohkuma, T.; Murata, K.; Yokozawa, T.; Kozawa, M.;

Katayama, E.; England, A. F.; Ikariya, T.; Noyori, R. Angew. Chem. Int. Ed. 1998, 37, 1703. (e) Ohkuma, T.; Koizumi,
M.; Doucet, H.; Pham, T.; Kozawa, M.; Murata, K.;
Katayama, E.; Yokozawa, T.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1998, 120, 13529. (f) Ohkuma, T.; Koizumi,
M.; Ikehira, H.; Yokozawa, T.; Noyori, R. Org. Lett. 2000,
2, 659. (g) Ohkuma, T.; Koizumi, M.; Yoshida, M.; Noyori,
R. Org. Lett. 2000, 2, 1749. (h) Ohkuma, T.; Takeno, H.;
Honda, Y.; Noyori, R. Adv. Synth. Catal. 2001, 343, 369.

- (5) Ohkuma, T.; Ooka, H.; Yamakawa, M.; Ikariya, T.; Noyori, R. J. Org. Chem. 1996, 61, 4872.
- (6) Matsumoto, T.; Murayama, T.; Mitsuhashi, S.; Miura, T. *Tetrahedron Lett.* **1999**, 40, 5043.
- (7) Ohkuma, T.; Ishii, D.; Takeno, H.; Noyori, R. J. Am. Chem. Soc. 2000, 122, 6510.
- (8) For the kinetic resolution of racemic ketones with RuH(η<sup>1</sup>-BH<sub>4</sub>)(binap)(dpen) under base-free conditions, see: Ohkuma, T.; Koizumi, M.; Muñiz, K.; Hilt, G.; Kabuto, C.; Noyori, R. J. Am. Chem. Soc. 2002, 124, 6508.
- (9) For the mechanism of asymmetric hydrogenation of simple ketones with the BINAP–DPEN–Ru(II) catalyst, see: Sandoval, C. A.; Ohkuma, T.; Muñiz, K.; Noyori, R. J. Am. Chem. Soc. 2003, 125, 13490.
- (10) See for example: (a) Brown, H. C.; Krishnamurthy, S. *Tetrahedron* 1979, *35*, 567. (b) Greeves, N. In *Comprehensive Organic Synthesis*, Vol. 8; Trost, B. M.; Fleming, I., Eds.; Pergamon: Oxford, 1991, 1. (c) Davis, A. P. In *Houben-Weyl*, 4th ed., Vol. E21d; Helmchen, G.; Hoffmann, R. W.; Mulzer, J.; Schaumann, E., Eds.; Thieme: Stuttgart, 1995, 4025.
- (11) Experimental Procedure of the Hydrogenation of 2a with Ketone:Ru = 100,000:1. Solid (*R*,*RR*)-7a (0.5 mg, 0.47 µmol), *t*-C<sub>4</sub>H<sub>9</sub>OK (180 mg, 1.73 mmol), and 2a (9.12 g, 51.2 mmol) were placed in a 500 mL glass autoclave equipped with a Teflon-coated magnetic stirring bar. Air present in the autoclave was replaced by argon. 2-Propanol (100 mL), which had been degassed by three freeze-thaw cycles, was added to the autoclave. The vessel was pressurized to 8 atm of hydrogen. The reaction mixture was vigorously stirred at 25 °C for 48 h, during which time the hydrogen cylinder was kept connected. After carefully venting the hydrogen gas in the apparatus, the solvent was removed under reduced pressure. The yield determined by GC was 100%. Subsequently, the residue was passed through a silica gel pad, eluted with a 1:4 EtOAchexane mixture giving (1S,2S)-5a (8.61 g, 93% yield, *cis:trans* = 100:0, 99.6% ee),  $[\alpha]_D^{23}$  +103.6 (*c* 2.02, CH<sub>3</sub>OH) {lit.  $[\alpha]_D^{27}$  -106 (*c* 0.20, CH<sub>3</sub>OH)}, 1*R*,2*R*-Isomer: Verbit, L.; Price, H. C. J. Am. Chem. Soc. 1972, 94, 5143.
- (12) The absolute configuration of (1S,2S)-**5b,c,e**, and -**6a**, as well as (3S,4R)-**12** was estimated according to the literature: Matsugi, M.; Itoh, K.; Nojima, M.; Hagimoto, Y.; Kita, Y. *Tetrahedron Lett.* **2001**, *42*, 6903. The *cis* alcohols were converted to the *trans*-(1R,2S) alcohols by stereoinversion of the hydroxyl-containing carbon, followed by acylation with  $3\beta$ -acetoxy- $\Delta^5$ -etiocholenic acid chloride. The <sup>1</sup>H NMR chemical shift at C(18)-CH<sub>3</sub> of the chiral auxiliary was higher than that derived from the 1S,2R-enantiomer.
- (13) Lee, J.; Askin, D.; Hoang, T. US Pat. Appl. 20020019532, 2002.
- (14) Absolute configuration of (2*S*,3*S*)-**10** was determined after removal of the *N*-benzyl group by hydrogenolysis.<sup>15</sup>
- (15) (a) Harrison, T.; Williams, B. J.; Swain, C. J.; Ball, R. G. Bioorg. Med. Chem. Lett. 1994, 4, 2545. (b) Stadler, H.; Bös, M. Heterocycles 1999, 51, 1067.

Synlett 2004, No. 8, 1383–1386 © Thieme Stuttgart · New York

- (16) Ladduwahetty, T.; Baker, R.; Cascieri, M. A.; Chambers, M. S.; Haworth, K.; Keown, L. E.; MacIntyre, D. E.; Metzger, J. M.; Owen, S.; Rycroft, W.; Sadowski, S.; Seward, E. M.; Shepheard, S. L.; Swain, C. J.; Tattersall, F. D.; Watt, A. P.; Williamson, D. W.; Hargreaves, R. J. J. Med. Chem. 1996, 39, 2907.
- (17) Klioze, S. S.; Ehrgott, F. J. US Pat. 4,312,876, 1982.
- (18) (a) Hjorth, S.; Carlsson, A.; Clark, D.; Svensson, K.; Wikström, H.; Sanchez, D.; Lindberg, P.; Hacksell, U.; Arvidsson, L.-E.; Johansson, A.; Nilsson, J. L. G. *Psychopharmacol.* **1983**, *81*, 89. (b) Herdeis, C.; Kaschinski, C.; Karla, R.; Lotter, H. *Tetrahedron: Asymmetry* **1996**, *7*, 867. (c) Amat, M.; Cantó, M.; Llor, N.; Escolano, C.; Molins, E.; Espinosa, E.; Bosch, J. J. Org. *Chem.* **2002**, *67*, 5343.